Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041741 | 0.84 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL20132611 | 0.81 | TGFBR1 (0.63) | TGFBR1 | |
| SCHEMBL3756838 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL22939902 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL13745783 | 0.75 | TGFBR1 (0.40) | TGFBR1 | |
| SCHEMBL2502307 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL13891590 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL12998315 | 0.75 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL19599267 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL18058990 | 0.74 | TGFBR1 (0.46) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-107406412-B | TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008014219-A2 | THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885 |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885 |
| US-10287295-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.